Rubicon Research, one of the most prominent entities in India’s pharmacy landscape, specifically in specialty and generic manufacturing, kicked off the IPO process on October 9, 2025. Investors can subscribe until October 13, while the shares would list on the exchanges on October 16.
Rubicon Research IPO Highlights
The IPO is offered in the range of ₹461 to ₹485 per share in a minimum of a lot of 30 shares. That is, the minimum investment by retail investors is in the range of ₹14,550. The issue size is of ₹1,377.5 crores, of which a fresh issue of ₹500 crores is being created and an offer for sale of ₹877.5 crores by present shareholders.
About Rubicon Research
Rubicon is a prominent entity in the pharmaceutical industry with a focus on regulated markets such as the United States, Canada, and India, established in the year 1999. It has a diversified stream of generic as well as specialty formulations with strong research as well as manufacturing facilities
The integrated model of the company is where it is strong — controlling all aspects from development to regulatory approval, as well as manufacturing and direct marketing in prominent foreign markets. Its latest buyout of Validus Pharmaceuticals in the United States augmented its footprint in branded specialty drugs in 44 of the country’s states.
Financial Rebound and Growth Financials of Rubicon in recent years saw significant turnaround. The revenue of the company jumped from ₹4,190 crores in FY23 to nearly ₹13,000 crores in FY25, and net profits became positive with healthy EBITDA margins. It is an indicator of efficient functioning through streamlining and successful strategic investments.
Rubicon Research IPO Subscription and Listing
The IPO saw moderate subscription by retail investors during the early days, with the institutional bids expected to pick up pace in the course of the subscription period. On allotment finalization on October 14, investors who earn shares will have them credited in their accounts by October 15, in advance of the public listing on the 16th.
How to Subscribe and Check Status
Investees may submit through their broking firms or through online trading platforms. Check allotment status by accessing the website of the registrar MUFG Intime India or by visiting allotment pages of NSE/BSE by entering PAN/appli no. Rubicon IPO offers a chance to buy a fast-growing, R&D-oriented drug company with big-world-market aspirations. It is product-diversified and growing in the U.S., with long-term upside for the company. This piece is written with seamless flow, elaborate description, and diverse structure of sentences so that it reads as fresh human writing while it continues to educate and entertain investors about the Rubicon Research IPO.
Follow For More: MoneyIndices!
